Colchicine, an anti-inflammatory medication used to treat gout, was safe, but did not significantly slow the progression of amyotrophic lateral sclerosis (ALS) in a small Phase 2 clinical trial. While some clinical measures suggested a possible benefit of a low dose of colchicine in slowing disease progression and extending…
ALS/MND 2023: Gout med fails to show efficacy in small trial
A couple days ago, as I was dishing up our family dinner, I popped a piece of chicken in my mouth and accidentally aspirated, drawing a small piece of chicken or phlegm into my lungs. I tried to cough it up, but wasn’t getting it out. I winced and pounded…
Eating foods with a higher glycemic index — those more likely to quickly raise a person’s blood sugar — is associated with slower functional declines and prolonged survival among people with amyotrophic lateral sclerosis (ALS), according to a recent analysis. Foods with high amounts of sugar include white bread…
Amylyx Pharmaceuticals is developing AMX0114, a new experimental treatment for amyotrophic lateral sclerosis (ALS) that’s designed to promote the health of nerve fibers by lowering levels of calpain-2, a protein. AMX0114 is being tested in preclinical studies with the aim of supporting an investigational new drug application (IND),…
As much as I’d love to be perceived as an I’ve-got-it-all-figured-out sort of ALS patient, I’m not. I have to invent mental strategies all the time to help me navigate through my day. Lately, I’ve been easily distracted and not paying attention to what I’m doing. Only then will…
Anxiety is common among people newly diagnosed with amyotrophic lateral sclerosis (ALS) and their family members, a small study from Sweden reports. However, symptoms of anxiety tended to ease about six or so months later for patients, while they continued to affect relatives, many who are caregivers, two years…
A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS) is expected to launch in the coming months, according to the therapy’s developer, Verge Genomics. Verge also announced that the upcoming trial will use Modality.AI, a…
My late husband, Jeff, was diagnosed with ALS just before Thanksgiving in 2018. His diagnosis had come swiftly — we’d first heard mention of ALS in July and his illness was confirmed in October, backed by a second opinion in November. Because there’s no definitive test for ALS,…
Health Canada has cleared ProJenX to open the third part of its ongoing Phase 1 clinical trial and begin testing the experimental therapy prosetin in people with amyotrophic lateral sclerosis (ALS). The first two parts of the PRO-101 trial (NCT05279755) involved healthy participants and showed that the…
“Count your blessings.” “You need to be thankful for what you do have.” People often give silver-lining advice to those facing hard things, and I’ve been on the receiving end of it since my husband, Todd, was diagnosed with ALS. I’ve also found myself offering similar sentiments to people…
Recent Posts
- Inflammatory bacterial sugar in gut may drive ALS risk: Study
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’